Affimed to Host Investor Event Highlighting AFM13 Clinical Development at 2022 ASH Annual Meeting
December 01 2022 - 4:05PM
Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a
clinical-stage immuno-oncology company committed to giving patients
back their innate ability to fight cancer, announced today that it
will host an Investor Event on December 10 during the 64th American
Society of Hematology (ASH) Annual Meeting in New Orleans, LA.
Investor event informationDate and
Time: Saturday, December 10 at 4:00 p.m. CST / 5:00
p.m. EST / 23:00 CETLocation: New Orleans, LA
and virtual
Affimed will host an investor event to review AFM13 clinical
data and development plans in CD30 expressing malignancies. The
investor event will take place in-person and virtually and a
webcast of the event will be available in the “Webcasts” section on
the “Investors” page of Affimed’s website
at https://www.affimed.com/investors/webcasts-and-corporate-presentation/.
To access the event via phone, please dial +1 (929) 205-6099 for
U.S. callers, or +44 (203) 481-5240 for international callers, and
reference meeting ID 847 4106 6227 approximately 15 minutes prior
to the call.
To reserve your place in the live event, please contact Alex
Fudukidis via e-mail at a.fudukidis@affimed.com.
A replay of the webcast/call will be archived on Affimed’s
website for 30 days after the call.
About AFM13AFM13 is a
CD30/CD16A bispecific Innate Cell Engager (ICE®) that is
investigated in Hodgkin Lymphoma (HL) and T cell lymphoma (TCL).
AFM13 has shown single agent efficacy in HL and TCL and is
currently being evaluated as monotherapy in a single arm
registration-directed trial in peripheral TCL (REDIRECT). In
addition, AFM13 showed high response rates in combination with the
anti-PD-1 antibody Keytruda® (ORR: 88%, CR: 46%) and in combination
with allogeneic cord blood-derived NK cells (ORR: 100%, CR: 71%).
Affimed recently entered into a partnership with Artiva to develop
AFM13 in combination with Artiva’s allogeneic, cryopreserved, NK
cell product AB-101 in HL and TCL.
About Affimed N.V.Affimed
(Nasdaq: AFMD) is a clinical-stage immuno-oncology company
committed to giving patients back their innate ability to fight
cancer by actualizing the untapped potential of the innate immune
system. The Company’s proprietary ROCK® platform enables a
tumor-targeted approach to recognize and kill a range of
hematologic and solid tumors, enabling a broad pipeline of
wholly-owned and partnered single agent and combination therapy
programs. The ROCK® platform predictably generates customized
innate cell engager (ICE®) molecules, which use patients’ immune
cells to destroy tumor cells. This innovative approach enabled
Affimed to become the first company with a clinical-stage ICE®.
Headquartered in Heidelberg, Germany, with offices in New York, NY,
Affimed is led by an experienced team of biotechnology and
pharmaceutical leaders united by a bold vision to stop cancer from
ever derailing patients’ lives. For more about the Company’s
people, pipeline and partners, please visit: www.affimed.com.
Investor Relations ContactAlexander
FudukidisDirector, Head of Investor RelationsE-Mail:
a.fudukidis@affimed.comTel.: +1 (917) 436-8102
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024